The European Medicines Agency’s Committee for Medicinal Products for Human Use has recommended the approval of Opdivo (nivolumab) in combination with platinum-based chemotherapy for the neoadjuvant treatment of resectable non-small cell lung cancer (NSCLC) at a high risk of recurrence in adult patients with tumour cell PD-L1 expression 1%.
The ...